The company was established in 2018 to accelerate ground-breaking research in Western Australia. BSP's business model progresses assets from discovery to US FDA Investigational New Drug Application (IND) submission readiness divestiture for initiation of clinical development. BSP's RNA-based therapeutics use splice switching oligonucleotides to precisely target key genes involved in causing ALS and Parkinson's disease, providing a precision medicinal therapeutic approach for patients suffering from neurological diseases.